Johnson & Johnson announced in September 2024 that its drug Tremfya received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active ulcerative colitis. This approval expands the therapeutic indications for Tremfya, a product on which Royalty Pharma holds royalty interests.
The expanded label for Tremfya is expected to drive increased sales for the product, thereby enhancing Royalty Pharma's royalty receipts. This development strengthens the performance of one of the company's existing commercial products.
This regulatory update contributes to the overall momentum of Royalty Pharma's diversified portfolio, supporting its consistent track record of growth in recurring cash inflows.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.